HCPCS code J7322 – Hyaluronan or derivative

Found our content helpful?

Key takeaways

HCPCS code J7322 covers both Hymovis and Hymovis One for intra-articular injection, billed per 1 mg under Medicare Part B.

Each 24 mg Hymovis syringe bills 24 units, so the 2-injection course totals 48 units across two dates of service.

Hymovis One is a 32 mg/4 mL syringe given as one injection, so a complete course bills 32 units on a single date.

Medicare coverage requires a confirmed osteoarthritis of the knee diagnosis and documented failure of conservative therapy per LCD A52420/A56157.

Pabau tracks injectable drug inventory, auto-populates J-codes, and streamlines CMS-1500 claim submission for in-office buy-and-bill programs.

HCPCS code J7322: Official description and code details

HCPCS code J7322 is a Level II code maintained by the Centers for Medicare and Medicaid Services (CMS). It describes a single drug unit within the broader J-code category for drugs and biologicals administered in a clinical setting.

J7322 falls under the AAPC HCPCS Level II J-code series alongside related hyaluronan codes (J7320 through J7325). The code stays specific to the Hymovis products, so it is not interchangeable with codes for other hyaluronic acid brands.

CMS revised the J7322 descriptor effective January 1, 2026 to name both Hymovis and Hymovis One. The short descriptor now reads “Hyaluronan, hymo or hymo one”. Older references that name only Hymovis predate that change.

About Hymovis and Hymovis One: the drugs behind J7322

Hymovis is a hyaluronan-based viscosupplement made by Fidia Farmaceutici and distributed in the United States by Fidia Pharma USA. It is indicated for the treatment of osteoarthritis of the knee in patients who have not responded to conservative non-pharmacologic therapy and simple analgesics.

Hymovis One is the same 8 mg/mL formulation in a larger syringe, approved by the FDA on April 9, 2025 under PMA P150010/S005. It delivers the full course in one injection rather than two, and it has no separate HCPCS code. Claims for it crosswalk to J7322.

• Formulation: Hymovis holds 24 mg of hyaluronan (HYADD4) in a 3 mL prefilled single-use syringe at 8 mg/mL, supplied in a 5 mL syringe barrel. Hymovis One holds 32 mg in 4 mL at the same 8 mg/mL concentration
• Treatment course: Hymovis is 2 intra-articular injections of one syringe each, given one week apart (day 0 and day 7). Hymovis One is a single intra-articular injection
• Mechanism: Viscosupplementation restores the viscoelastic properties of synovial fluid, reducing pain and improving joint mobility in knee osteoarthritis
• Administration setting: Physician office or outpatient facility; buy-and-bill model applies
• Why a J-code: Physician-administered drugs dispensed during an office visit are billed under HCPCS Level II J-codes rather than through a pharmacy benefit

Because J7322 is billed per 1 mg, the milligrams in the syringe set the units. A Hymovis injection generates 24 billing units, and the 2-injection course totals 48 across two dates of service. A Hymovis One injection generates 32 units on one date.

Payer policy caps a Hymovis course at 48 units per knee, so anything above that figure gets cut back or denied. Confirm the cap the payer applies to Hymovis One before you bill it, since many policies still name the 2-injection product.

J7322 billing units and dosage

Unit miscalculation is the most common billing error on J7322 claims. The code is structured per 1 mg, so the administered dose in milligrams converts directly to the number of units on the claim.

One Hymovis syringe delivers 24 mg, which means 24 units. A Hymovis One syringe delivers 32 mg, which means 32 units. The chart below sets those counts against the 8-unit figure that circulates in secondary coding references.

NDC reporting on Medicare Part B drug claims is required by CMS for separately payable drugs. Verify current CMS transmittals with your Medicare Administrative Contractor (MAC) to confirm the NDC field requirements in your jurisdiction. Guidance can change through a Change Request.

J7322 Medicare coverage criteria

Medicare covers J7322 for knee osteoarthritis, but coverage is conditional. Two Local Coverage Determinations govern eligibility: LCD A52420 and LCD A56157, depending on the MAC jurisdiction. Both share the same core criteria.

• Confirmed diagnosis: Osteoarthritis of the knee, documented in the medical record with applicable ICD-10-CM diagnosis code (M17 series)
• Conservative therapy failure: The patient must have tried and failed appropriate conservative, non-pharmacologic therapy and/or simple analgesics before viscosupplementation is considered medically necessary
• Documentation of failure: The medical record must show the specific conservative treatments attempted, the duration of treatment, and the patient’s inadequate response
• Frequency limits: Medicare generally covers one course of treatment per knee per year, per the applicable LCD. Verify the current frequency limitation in your MAC jurisdiction before you schedule a repeat course
• Bilateral knee: Coverage may apply to both knees if each meets the criteria independently, billed with appropriate ICD-10 laterality codes

ICD-10 diagnosis codes to pair with J7322

Every J7322 claim must carry a covered ICD-10 diagnosis code. The M17 series covers primary and other osteoarthritis of the knee. Use the most specific laterality available.

Always verify covered diagnosis codes against the current LCD in effect for your MAC. The list above reflects commonly accepted codes; individual LCD versions may specify inclusions or exclusions that differ by jurisdiction. Confirm the beneficiary’s active coverage before you administer the injection.

J7322 reimbursement rate and fee schedule

Medicare pays J7322 as a Part B physician-administered drug, using the Average Sales Price (ASP) plus a 6% statutory add-on. CMS updates ASP-based rates quarterly.

Because ASP changes every quarter, always pull the current CMS ASP payment file before setting your charge master or estimating reimbursement for a treatment cycle. Rates cited in older billing guides may already be out of date.

Medicaid and commercial payer coverage for J7322

Medicaid coverage for viscosupplementation is set state by state. Some programs cover Hymovis with prior authorization and step-therapy conditions. Others limit coverage to one preferred hyaluronic acid product, and a few exclude the class outright. Check the patient’s own state program before you order the syringes.

Commercial plans and Medicare Advantage plans apply their own medical policy. Expect a prior authorization requirement, documented failure of conservative care, and a unit cap set at one full course.

Many plans also name a preferred hyaluronan, so a clinically appropriate J7322 claim can still be denied as non-preferred.

That kind of denial needs a formulary exception or a switch to the covered product, not a medical-necessity appeal. Plans also differ on how soon a second course can be billed.

Record each answer in a payer checklist your schedulers can see, so the requirement gets checked before the appointment.

Companion CPT code for injection administration

J7322 covers only the drug. The injection procedure is billed separately with an administration code on the same claim. For a knee joint injection, two CPT codes commonly apply.

Confirm your 20610 or 20611 choice against current AMA CPT codebook guidance and your payer’s policy before billing. Some commercial payers and Medicare Advantage plans add documentation requirements for ultrasound-guided injections.

Place of service affects payment too. POS 11 (office) and POS 22 (outpatient hospital) both apply, depending on the setting. Check that the claimed POS matches where the injection was given.

Buy and bill process for HCPCS code J7322 (Hymovis and Hymovis One)

Hymovis is acquired and billed under the physician buy-and-bill model. The practice purchases the drug, administers it, and then bills the payer for both the drug and the administration service.

Getting the workflow right at each step prevents denials and protects cash flow. A charge-capture check that confirms every required field before submission is the most effective safeguard.

1. Acquire: Order Hymovis or Hymovis One from an authorized wholesaler or distributor. Hymovis ships as two single-use syringes, one for each injection date, while Hymovis One ships as a single syringe. Verify the NDC on receipt and record every lot number and expiration date in your drug log.
2. Store: Keep the syringes in their original package at room temperature, below 25 degrees C (77 degrees F), and never freeze them. Maintain a storage log against the labeled conditions.
3. Verify coverage before administering: Confirm active Medicare or commercial coverage. Check that the knee OA diagnosis and the conservative-therapy failure are both documented. For commercial plans, check whether prior authorization is required before the first injection.
4. Administer: Administer the intra-articular injection and document the administration note with date, dose, lot number, expiration date, and provider attestation.
5. Complete the claim: Bill J7322 with the units in the syringe you used, 24 for Hymovis or 32 for Hymovis One, plus the 11-digit NDC. Add CPT 20610 or 20611, the applicable ICD-10-CM M17 code and the correct place of service. Submit on CMS-1500 (office) or UB-04 (outpatient hospital).
6. Reconcile: Match the remittance advice against expected ASP+6% reimbursement. Underpayment or denial requires review of the explanation of benefits for applicable remark codes before resubmitting.

Prior authorization requirements

Medicare Fee-for-Service generally does not require prior authorization for J7322 under traditional Medicare. However, Medicare Advantage (Part C) plans operate under their own PA rules.

Most commercial payers require PA for viscosupplementation. Key documentation for a PA request includes:

• Confirmed OA knee diagnosis with applicable ICD-10 code
• Documented conservative therapy attempts and duration (physical therapy, analgesics, weight management)
• Physician attestation that conservative therapy failed to provide adequate relief
• Radiographic evidence of knee OA (X-ray or MRI report) where required by the payer

Documentation requirements for J7322 claims

Inadequate documentation is the leading cause of post-payment audits on viscosupplementation claims.

Compliant billing for J7322 requires the medical record to support every coverage criterion in the applicable LCD. The goal is a claim that pays the first time, without a request for records.

• Diagnosis documentation: A physician note or consultation confirming osteoarthritis of the knee, with the ICD-10-CM code clearly linked to the injection order
• Conservative therapy record: Dates and types of prior treatments (NSAID use, physical therapy referrals, cortisone injections), with duration and outcome documented
• Injection administration note: Date of service, provider name and drug name. Record the dose administered, which is 24 mg in 3 mL for Hymovis or 32 mg in 4 mL for Hymovis One. Also record the lot number, the expiration date and the injection site (right, left or bilateral knee)
• NDC on the claim: The 11-digit NDC must appear in Box 24D of the CMS-1500 with qualifier N4. Report the NDC units in the field your MAC specifies
• Ordering provider information: NPI of the administering and, where applicable, ordering physician

Retain all documentation for the standard Medicare audit retention period (currently 7 years). Payers conducting post-payment audits typically request the complete medical record, not just the claim face sheet.

Related HCPCS codes for hyaluronan products

J7322 is one of several HCPCS codes covering viscosupplementation products, and coders confuse them with each other often. Each code is product-specific and not interchangeable.

The table below covers the full J7320-J7325 series.

Each code is tied to specific products, so clinical similarity is never a reason to substitute one for another. J7322 covers two, and both are Fidia’s Hymovis formulations. Billing J7321 when Hymovis was administered is a coding error, even though both products are hyaluronic acid.

Two other single-injection products sit just outside this range. Gel-One is J7326 and Monovisc is J7327, so neither belongs on a J7320-J7325 crosswalk. Bill the code that matches the NDC on the syringe you used.

Common billing errors and how to avoid them

Five errors account for most J7322 denials and underpayments. Each one is preventable at the charge-capture step, before the claim leaves the practice.

Error 1: Billing 8 units instead of the full syringe

An 8 mg/4 mL figure circulates in secondary coding references, and it matches neither product. Hymovis comes as a 3 mL syringe at 8 mg/mL, so one injection delivers 24 mg and bills 24 units. Hymovis One comes as a 4 mL syringe at the same concentration, so it delivers 32 mg and bills 32 units.

A line submitted at 8 units still pays, which is why the shortfall rarely shows up as a denial. A full Hymovis course is 48 units across two dates. Read the dose off the syringe label and the package insert, not a secondary coding summary.

Error 2: Using the same number for units and NDC quantity

One J7322 line carries two different quantities. The HCPCS unit count is 24, because the code pays per milligram. The NDC quantity is 3 with the ML qualifier, because that is the volume in the syringe. Copying either figure into the other field produces a unit-mismatch rejection.

Error 3: Billing a neighboring hyaluronan code

The neighboring hyaluronan codes do not share one billing unit. J7320 and J7325 bill per 1 mg like J7322, while J7321, J7323 and J7324 bill per dose. A mis-keyed code therefore carries the wrong unit count as well as the wrong product. Match the code to the NDC on the syringe you used.

Error 4: Injecting before the payer’s conditions are met

Traditional Medicare does not require prior authorization, which makes it tempting to treat every plan the same way. Medicare Advantage and most commercial plans do require it.

Injecting first turns a covered course into an uncompensated one, because retroactive authorization is rarely granted. Confirm the requirement and the conservative-therapy record at scheduling.

Error 5: Quoting reimbursement from a stale ASP file

ASP changes every quarter, so a charge master built on last year’s file is already wrong. Across a 24-unit line and a 48-unit course, a small per-milligram change adds up quickly. Pull the current CMS ASP file each quarter and update the drug’s cost and charge together.

How Pabau simplifies HCPCS code J7322 billing workflows

The code itself is the simple part. Errors accumulate in the steps around it. Billers copy J-code details from a paper drug log into the claim. NDC numbers get transcribed by hand, and the inventory record sits outside the billing system.

Practice management software like Pabau keeps that trail in one place. Pabau’s claims management software connects the dispensing record to the claim.

When a clinician administers either product, the drug record updates and J7322 reaches the claim with the stored dose for that syringe. The NDC captured at dispensing carries through to the CMS-1500.

• Inventory management: Track Hymovis and Hymovis One syringes by lot number and expiration date. Pabau flags low stock and expiring inventory before it becomes a billing problem.
• Stored J-code and units: Hold J7322 and the matching unit count on each product record, 24 for Hymovis and 32 for Hymovis One. The same figures then reach every claim line without a per-claim calculation.
• NDC capture at dispensing: Record the NDC at the point of administration. It flows into the claim instead of needing a separate lookup later.
• Claim preparation: Pabau assembles the CMS-1500 with the drug line, the administration code and the diagnosis already attached, so fewer fields are keyed by hand.

Practices running denial management workflows across several in-office drug programs feel this most. Centralizing inventory, administration records and claim preparation in one platform closes the most common error pathways.

Streamline your in-office drug billing with Pabau

Pabau tracks injectable inventory, auto-populates HCPCS J-codes, and prepares CMS-1500 claims for buy-and-bill programs. See how practices billing viscosupplementation use Pabau to reduce claim errors and speed up reimbursement.

Book a demo

Conclusion

Billing HCPCS code J7322 correctly comes down to three details. The unit count follows the syringe, 24 units for Hymovis and 32 for Hymovis One.

The diagnosis pairing comes from the M17 series with laterality. The documentation trail has to show conservative therapy failure before the first injection. Miss any one of them and you are looking at a denial or a post-payment audit.

Pabau’s inventory and claims management tools connect dispensing records to claim preparation. J7322 units, NDC numbers and diagnosis codes move from the clinical record to the CMS-1500 without manual re-entry.

To see how practices running in-office viscosupplementation programs handle a J7322 course end to end, book a demo.

Continue your research

Need to understand the full claim submission process? What is medical billing covers the end-to-end claim lifecycle for physician-administered drugs and services.

Getting ERA remittances back with denial codes on J7322? Denial management in healthcare explains how to read remark codes and build an appeals workflow.

Want to understand how your revenue cycle connects to ASP-based reimbursement? What is revenue cycle management maps the full cycle from charge capture to payment posting.

Frequently asked questions